European life sciences investment firm Life Sciences Partners (LSP) closed its new life sciences fund, at $280m.
LSP 5, which surpassed its $170m target, primarily focuses on Europe, looking to invest in around 20 companies across the areas of drug development, medical devices and diagnostics.
Launched in 2014, the fund has already started to invest, taking positions in 9 companies including:
– Irish medical device company Neuravi, active in acute ischemic stroke,
– Swiss-based immuno-oncology company Nouscom, and
– Kuros Biosciences, focused on tissue repair and regeneration and recently listed on the Swiss Stock Exchange.
Led by partners René Kuijten, Joachim Rothe, Martijn Kleijwegt, Joerg Neermann, John de Koning and Fouad Azzam, LSP has invested in approx. 100 innovative enterprises including Dutch companies Crucell, Merus, Prosensa, Sapiens; Belgian companies argenx, Movetis; German companies Activaero, Jerini, U3 Pharma; Swiss company Okairos and Danish company Zealand Pharma.
The firm, which has over $1.2 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, also invests in public companies through its Euronext-listed LSP Life Sciences Fund (Bloomberg: LSP NA).